The Division of Hematologic Malignancies, as part of the Sydney Kimmel Comprehensive Cancer Center (SKCCC) at Thomas Jefferson University, focuses on cancers that originate in the blood, bone marrow, or lymphatic system, diseases that profoundly impact the body’s ability to produce healthy blood cells and maintain a strong immune response. These conditions develop when abnormal blood-forming cells proliferate uncontrollably, displacing normal cells and disrupting essential functions such as oxygen transport, infection control, and blood clotting. The major categories, leukemia, lymphoma, and multiple myeloma, each affect different components of the hematologic system, yet all share the hallmark of unchecked cellular growth. Leukemias arise in the bone marrow and bloodstream, lymphomas involve the lymphatic system, and multiple myeloma originates from malignant plasma cells within the bone marrow.
The Division of Hematologic Malignancies is dedicated to advancing both patient care and scientific discovery in these complex diseases. As we recruit medical students to join our program, we emphasize a seamless integration of clinical training and cutting-edge research. Students engage directly with patients while contributing to innovative studies exploring emerging therapies, including targeted treatments, cellular therapies, and next-generation immunotherapies. This immersive experience allows students to deepen their understanding of hematologic malignancies and participate meaningfully in the development of new diagnostic and therapeutic strategies, preparing them to become future leaders in hematology, oncology, and translational research.